Picture loading failed.

Anti-MS4A1 therapeutic antibody (Pre-made Ocaratuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ocaratuzumab (AME-133v, LY2469298) is a humanized monoclonal antibody designed for the treatment of cancer and autoimmune disorders. The antibody is engineered for enhanced affinity to the CD20 antigen on B-lymphocytes, increased antibody-dependent cell-mediated cytotoxicity (ADCC), and for improved treatment of low-affinity FcγRIIIa allotypes.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-387-1mg 1mg 3090
GMP-Bios-ab-387-10mg 10mg 21890
GMP-Bios-ab-387-100mg 100mg 148000
GMP-Bios-ab-387-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-MS4A1 therapeutic antibody (Pre-made Ocaratuzumab biosimilar,Whole mAb)
INN Name Ocaratuzumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesApplied Molecular Evolution;MENTRIK Biotech
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedFollicular lymphoma;Non-Hodgkin's lymphoma;Rheumatoid arthritis
Development Techna